UNIVERSAL Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Sham Mailankody, MBBS¹, Michaela Liedtke, MD², Surbhi Sidana, MD³, Jeffrey V. Matous, MD⁴, Saurabh Chhabra, MD, MS⁵, Olalekan O. Oluwole, MBBS, MPH⁶, Shahbaz A. Malik, MD⁷, Shaji Kumar, MD⁸, Rajneesh Nath, MD⁹, Faiz Anwer, MD¹⁰, Jose Carlos Cruz, MD¹¹, Sundar Jagannath, MD¹², Myo Htut¹³, Noopur S. Raje, MD¹⁴, David S. Siegel, MD, PhD¹⁵, Erin E. Karski, MD¹⁶, Wade Lovelace¹⁶, Afrodite Lourbakos, PhD¹⁶, Arun Balakumaran, MD, PhD¹⁶, and Parameswaran Hari⁵

¹ Myeloma Service and Cellular Therapeutics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; ² Division of Hematology, Department of Medicine, Stanford University, Stanford, CA; ³ Division of BMT and Cell Therapy, Stanford University Hospital, Stanford, CA; ⁴ Colorado Blood Cancer Institute, Denver, CO; ⁵ Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI; ⁶ Vanderbilt University Medical Center, Nashville, TN; ⁷ Bone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX; ⁸ Mayo Clinic, Rochester, MN; ⁹ Banner MD Anderson Cancer Center, Gilbert, AZ; ¹⁰ Taussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH; ¹¹ Texas Transplant Institute, San Antonio, TX; ¹² Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY; ¹³ Comprehensive Cancer Center, City of Hope National Medical Center, Duarte, CA; ¹⁴ Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA; ¹⁵ John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ; ¹⁶ Allogene Therapeutics, South San Francisco, CA.

Srinand Ponnathapura Nandakumar, PhD, formally of Allogene Therapeutics, provided additional support.

Presented by Sham Mailankody, MBBS

NCT04093596
The First Allogeneic anti-BCMA CAR T Study for R/R Multiple Myeloma

- BCMA cell therapy has demonstrated unprecedented efficacy, but is not readily available to all patients
- Allogeneic chimeric antigen receptor (CAR) T cell therapy has the potential for all eligible patients to receive therapy on demand and supports re-dosing
- ALLO-715 (anti-BCMA) is an allogeneic CAR T cell product utilizing TALEN®* gene editing specifically designed to
  - Disrupt TCRα constant gene – to reduce the risk graft-versus-host disease (GvHD)
  - Edit CD52 gene – permits use of ALLO-647 (a humanized anti-CD55 mAb) to selectively deplete host T cells while protecting donor cell

*TALEN® gene editing is a technology pioneered and controlled by Cellectis.
UNIVERSAL: First Allogeneic BCMA CAR T in Multiple Myeloma

Phase 1, Open-label, Multicenter Dose Escalation Study Enrolling in Fourteen US Centers

Key Eligibility Criteria
- Relapsed/refractory multiple myeloma
- ≥3 prior therapies including IMiD, proteasome inhibitor & anti-CD38
- Refractory to last prior therapy
- ECOG 0 or 1
- No donor-specific antibodies
- No prior systemic therapy within 2 weeks

Primary Endpoints
- Safety and tolerability

Secondary and Exploratory Endpoints
- Recommended ALLO-715 P2 dose and lymphodepletion (LD) regimen
- Anti-tumor activity (ORR, duration of response, PFS, and MRD)
- ALLO-715 cellular kinetics (blood levels of anti-BCMA CAR T cells)
- ALLO-647 pharmacokinetics (serum ALLO-647 concentrations)

Three Arms of the Study
- Part A: Dose Escalation of ALLO-715 with two different lymphodepletion regimens
- Part B: Evaluation of ALLO-715 in combination with nirogacestat
- Part C: Evaluation of consolidation dosing with ALLO-715

American Society of Hematology
UNIVERSAL: First Allogeneic BCMA CAR T in Multiple Myeloma

Design for Part A*

ALLO-715 Dose Escalation: 40, 160, 320, 480 x 10^6 CAR T cells

<table>
<thead>
<tr>
<th>Lymphodepletion Regimens (FCA**, CA†)</th>
<th>Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fludarabine</td>
<td>30 mg/m^2/day x 3 days</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>300 mg/m^2/day x 3 days</td>
</tr>
<tr>
<td>ALLO-647</td>
<td>13 to 30 mg x 3 days</td>
</tr>
</tbody>
</table>

* Parts B (combination of ALLO-715 + nirogacestat) and C (consolidation regimen) are not reported here
** FCA conditioning with fludarabine, cyclophosphamide, and ALLO-647
† CA conditioning with cyclophosphamide and ALLO-647
Patient Flow

*Median Time from Enrollment to Start of Treatment for All Patients: 5 Days*

<table>
<thead>
<tr>
<th>CAR+ T Cell Dose</th>
<th>FCA39</th>
<th>FCA60</th>
<th>FCA90</th>
<th>CA39</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 x 10^6 Cells (DL1)</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>160 x 10^6 Cells (DL2)</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>3</td>
</tr>
<tr>
<td>320 x 10^6 Cells (DL3)</td>
<td>11</td>
<td>10</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>480 x 10^6 Cells (DL4)</td>
<td>3</td>
<td>3</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Overall median follow-up time = 4 Months

- Patient flow includes patients enrolled in Part A of study
- Part A was a single dose of ALLO-715 cells in dose escalation which was previously presented
- Multiple LD regimens were evaluated at DL3 and DL4
- This presentation focuses on the results from the expansion of DL3

5 patients became ineligible due to organ failures from rapidly progressing disease

Median Time from Enrollment to Start of Treatment for All Patients: 5 Days

Part A Enrolled (N=48)

Part A Safety Population (N=43)

Part A Efficacy Population (N=43)
Heavily Pretreated Patients with Refractory Advanced-Stage Disease

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Safety Population (N=43)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, median (range), years</td>
<td>64 (46, 77)</td>
</tr>
<tr>
<td>Gender, %</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>63</td>
</tr>
<tr>
<td>Female</td>
<td>37</td>
</tr>
<tr>
<td>ECOG PS, %</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>49</td>
</tr>
<tr>
<td>1</td>
<td>51</td>
</tr>
<tr>
<td>ISS Stage III, %</td>
<td>19</td>
</tr>
<tr>
<td>High-risk cytogenetics*, %</td>
<td>37</td>
</tr>
<tr>
<td>Extramedullary disease, %</td>
<td>21</td>
</tr>
<tr>
<td>High tumor burden at screening†, %</td>
<td>33</td>
</tr>
<tr>
<td>Time since initial diagnosis, median (range), years</td>
<td>4.9 (0.9, 26.4)</td>
</tr>
<tr>
<td>Number of prior anti-myeloma regimens, median (range)</td>
<td>5 (3, 11)</td>
</tr>
<tr>
<td>Prior autologous SCT, %</td>
<td>91</td>
</tr>
<tr>
<td>Penta exposed/Penta-refractory, %</td>
<td>84/42</td>
</tr>
</tbody>
</table>

- Patients had advanced disease
  - 19% of patients had ISS Stage III
  - 21% of patients had extramedullary disease
- Heavily pretreated patients in study
  - Median of 5 prior lines of therapy
  - All patients were refractory to last line
    - 91% were triple refractory and 42% were penta-refractory
- No patient received bridging therapy

* High-risk cytogenetics is defined as del 17p, t(4;14), or t(14;16)
† High tumor burden considered when more than 50% plasma cells in bone marrow
ALLO-715 and ALLO-647 Demonstrated Manageable Safety Profile

- Manageable safety profile with low-grade and reversible neurotoxicity and no GvHD
  - 14% of patients with AEs of potential low-grade neurotoxicity
  - Low use of tocilizumab 23% and steroids 14%

<table>
<thead>
<tr>
<th>TEAE of Interest* (N=43)</th>
<th>Grade 1</th>
<th>Grade 2</th>
<th>Grade 3</th>
<th>Grade 4</th>
<th>Grade 5</th>
<th>All Grades</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Cytokine Release Syndrome</td>
<td>13 (30)</td>
<td>10 (23)</td>
<td>1 (2)</td>
<td>0</td>
<td>0</td>
<td>24 (56)</td>
</tr>
<tr>
<td>Neurotoxicity†</td>
<td>4 (9)</td>
<td>2 (5)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>6 (14)</td>
</tr>
<tr>
<td>Graft-versus-Host Disease</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Infection‡</td>
<td>3 (7)</td>
<td>10 (23)</td>
<td>7 (16)</td>
<td>0</td>
<td>3 (7)</td>
<td>23 (54)</td>
</tr>
<tr>
<td>Infusion Reaction to ALLO-647</td>
<td>7 (16)</td>
<td>5 (12)</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>12 (28)</td>
</tr>
</tbody>
</table>

- 20 (47%) patients with an SAE
- 30 (70%) patients experienced Gr3+ neutropenia
- 3 Gr5 infections; 2 previously reported and an additional one due to sepsis

* Number of patients with AE occurring from the start of study drug up to subsequent anti-cancer therapy. For patients reporting more than one AE within a preferred term, only one AE with the maximum grade is reported
† Analysis done using a broad SMQ of noninfectious encephalopathy/delirium with adjudication by clinical review
‡ All infections (bacterial, fungal, and viral) included

Data Cutoff Date: October 14, 2021
**Encouraging Efficacy Seen with Additional Patients at DL3**

<table>
<thead>
<tr>
<th>Cell Dose &amp; LD Regimen</th>
<th>DL3 (320M CAR+ T Cells)*</th>
<th>DL4 (480M CAR+ T Cells)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FCA39 N=11</td>
<td>FCA60 N=10</td>
</tr>
<tr>
<td></td>
<td>7 (64) (31, 89)</td>
<td>8 (80) (44, 98)</td>
</tr>
<tr>
<td>ORR†, n (%) (95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>VGPR+ Rate, n (%)</td>
<td>5 (46)</td>
<td>5 (50)</td>
</tr>
<tr>
<td>CR/sCR Rate, n (%)</td>
<td>3 (27)</td>
<td>3 (30)</td>
</tr>
<tr>
<td>mDOR, months (95% CI)</td>
<td>8.3 (3.4, 11.3)</td>
<td>NE (5.6, NE)</td>
</tr>
<tr>
<td>Median follow-up, months (range)**</td>
<td>3.3 (0.5, 3.8)</td>
<td>3.8 (3.1, 11.2)</td>
</tr>
</tbody>
</table>

- In the FCA 320M CAR+ cell dose group, 17 patients (71%) achieved an overall response rate (ORR)
- 11 (46%) were VGPR+, of those 6 (25%) were CR/sCR

* Three patients treated with 320M CAR+ cells and the CA LD regimen are not included above. Two of those responded with one pt achieving a CR
† Clinical response evaluation was based on IMWG response criteria, Kumar et al, 2016
** Median follow-up is for censored pts
320M CAR T+ Cell Dose Achieves Durable Responses

- Median time to response was 16 days
- In the expansion of DL3 FCA, 9 pts with an initial response remain in response with median duration of response of 8.3 months
  - Of those with a confirmed response of VGPR+, 92% were MRD negative
  - MRD negativity is associated with a durable response and period of progression-free survival
Reduced sBCMA on D28 Associated with Clinical Response

Baseline sBCMA levels were comparable across all treated patients.

sBCMA levels were 10x lower in responders compared to non responders.

sBCMA suppression is associated with responses.

Baseline D+28

CR (n=6)

VGPR (n=4)

PR (n=5)

NR (n=6)

Response

sBCMA result ng/mL

1

10

100

1000

0.1

3

10

20

40

60

100

D0 sBCMA equals Baseline/Screen levels
Data shown include subjects in FCA39 and FCA60 cohorts
Summary

- ALLO-715 UNIVERSAL Trial is the first allogeneic anti-BCMA CAR T study to demonstrate safety and substantial efficacy in MM
- “Off-the-shelf” AlloCAR Ts have potential to addresses significant unmet need in patients with rapidly progressive disease
  - No bridging therapy required
  - Median time from enrollment to start of therapy of 5 days
  - 90% enrolled patients received treatment
- ALLO-715 with ALLO-647 is well tolerated with low-grade CRS, low-grade reversible neurotoxicity, no GvHD, and manageable safety
- 71% ORR and 46% VGPR+ with 320M cell dose and FCA comparable to approved autologous CAR T therapy
  - 92% VGPR+ responses were MRD negative
  - 8.3 months median durability of response
- ALLO-715 consolidation with two doses and ALLO-715 in combination with nirogacestat are also being evaluated; Next generation anti-BCMA TurboCAR (ALLO-605) currently in Phase 1 development
THANK YOU

To patients, their families and caregivers, clinical trial investigators, and sites
Sham Mailankody has received research support for clinical trials from Juno Therapeutics, Janssen Pharmaceuticals, Fate Therapeutics, Takeda, and Allogene Therapeutics. He has received honoraria from Physicians’ Education Resource and Plexus Communications and provided consultancy to Legend Biotech and Evicore.